Gyre Therapeutics (GYRE) Shares Outstanding (Weighted Average) (2010 - 2026)
Gyre Therapeutics (GYRE) reported Shares Outstanding (Weighted Average) of $91.3 million for Q1 2026, up 5.67% year-over-year from $86.4 million in Q1 2025, and up 2.21% on a QoQ basis from $89.3 million in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $91.3 million in Q1 2026.
- Quarterly Shares Outstanding (Weighted Average) rose 5.67% year-over-year to $91.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91.3 million (up 5.67% YoY) and the FY2025 annual result came in at $89.3 million, up 4.99% from the prior year.
- Shares Outstanding (Weighted Average) rose to $91.3 million in Q1 2026 per GYRE's latest filing, from $89.3 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $91.3 million in Q1 2026 and bottomed at $31.5 million in Q1 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $83.3 million (2024), against an average of $70.4 million.
- Peak annual rise in Shares Outstanding (Weighted Average) reached 107.53% in 2022, while the deepest fall reached 0.33% in 2022.
- Tracing GYRE's Shares Outstanding (Weighted Average) over 5 years: stood at $63.6 million in 2022, then climbed by 3.53% to $65.8 million in 2023, then advanced by 29.26% to $85.1 million in 2024, then rose by 4.99% to $89.3 million in 2025, then advanced by 2.21% to $91.3 million in 2026.
- Per Business Quant, the three latest GYRE Shares Outstanding (Weighted Average) figures stand at $91.3 million (Q1 2026), $89.3 million (Q4 2025), and $90.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 91.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91.32 Mn |
| Dec 31, 2025 | 89.34 Mn |
| Sep 30, 2025 | 90.85 Mn |
| Jun 30, 2025 | 87.30 Mn |
| Mar 31, 2025 | 86.42 Mn |
| Dec 31, 2024 | 85.09 Mn |
| Sep 30, 2024 | 84.81 Mn |
| Jun 30, 2024 | 84.38 Mn |
| Mar 31, 2024 | 83.27 Mn |
| Dec 31, 2023 | 65.83 Mn |
| Sep 30, 2023 | 63.59 Mn |
| Jun 30, 2023 | 63.59 Mn |
| Mar 31, 2023 | 63.59 Mn |
| Dec 31, 2022 | 63.59 Mn |
| Sep 30, 2022 | 31.48 Mn |
| Jun 30, 2022 | 31.47 Mn |
| Mar 31, 2022 | 31.46 Mn |
| Dec 31, 2021 | 30.64 Mn |
| Sep 30, 2021 | 31.38 Mn |
| Jun 30, 2021 | 31.35 Mn |
| Mar 31, 2021 | 28.39 Mn |
| Dec 31, 2020 | 19.18 Mn |
| Sep 30, 2020 | 22.07 Mn |
| Jun 30, 2020 | 16.24 Mn |
| Mar 31, 2020 | 14.59 Mn |
| Dec 31, 2019 | 12.00 Mn |
| Sep 30, 2019 | 11.99 Mn |
| Jun 30, 2019 | 11.98 Mn |
| Mar 31, 2019 | 11.96 Mn |
| Dec 31, 2018 | 10,194.00 |
| Sep 30, 2018 | 10.97 Mn |
| Jun 30, 2018 | 10.47 Mn |
| Mar 31, 2018 | 8.99 Mn |
| Dec 31, 2017 | 1.75 Mn |
| Sep 30, 2017 | 4.31 Mn |
| Jun 30, 2017 | 3.88 Mn |
| Mar 31, 2017 | 906,048.00 |
| Dec 31, 2016 | 12,039.00 |
| Sep 30, 2016 | 789,796.00 |
| Jun 30, 2016 | 763,138.00 |
| Mar 31, 2016 | 762,007.00 |
| Dec 31, 2015 | 295,272.00 |
| Sep 30, 2015 | 2.07 Mn |
| Jun 30, 2015 | 373,633.00 |
| Mar 31, 2015 | 372,489.00 |
| Dec 31, 2014 | 367,586.00 |
| Sep 30, 2014 | 368,461.00 |
| Jun 30, 2014 | 33.79 Mn |
| Mar 31, 2014 | 33.75 Mn |
| Dec 31, 2013 | 365,214.00 |
| Sep 30, 2013 | 33.64 Mn |
| Jun 30, 2013 | 33.63 Mn |
| Mar 31, 2013 | 33.62 Mn |
| Dec 31, 2012 | 33.48 Mn |
| Sep 30, 2012 | 33.49 Mn |
| Jun 30, 2012 | 33.40 Mn |
| Mar 31, 2012 | 33.39 Mn |
| Dec 31, 2011 | 31.64 Mn |
| Sep 30, 2011 | 33.38 Mn |
| Jun 30, 2011 | 30.73 Mn |
| Mar 31, 2011 | 29.00 Mn |
| Dec 31, 2010 | 28.54 Mn |
| Sep 30, 2010 | 28.48 Mn |
| Jun 30, 2010 | 28.51 Mn |